You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFospropofol
Accession NumberDB06716  (DB05279)
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionFospropofol is a water soluble prodrug and is converted to propofol in the liver. Fospropofol is a short acting hypnotic/sedative/anesthetic agent. Unlike propofol, does not cause injection-site pain as it is unable to activate TRPA1. FDA approved in December 2008. Fospropofol is classified as a Schedule IV controlled substance in the United States' Controlled Substances Act.
Structure
Thumb
Synonyms
Fospropofol
External Identifiers
  • GPI 15715
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Lusedrainjection35 mg/mLintravenousEisai, Inc2008-12-12Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AquavanNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Fospropofol disodium
258516-87-9
Thumb
  • InChI Key: LWYLQNWMSGFCOZ-UHFFFAOYSA-L
  • Monoisotopic Mass: 332.07654958
  • Average Mass: 332.2403
DBSALT000090
Categories
UNIILZ257RZP7K
CAS number258516-89-1
WeightAverage: 288.2766
Monoisotopic: 288.112660294
Chemical FormulaC13H21O5P
InChI KeyInChIKey=QVNNONOFASOXQV-UHFFFAOYSA-N
InChI
InChI=1S/C13H21O5P/c1-9(2)11-6-5-7-12(10(3)4)13(11)17-8-18-19(14,15)16/h5-7,9-10H,8H2,1-4H3,(H2,14,15,16)
IUPAC Name
[2,6-bis(propan-2-yl)phenoxymethoxy]phosphonic acid
SMILES
CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cumenes. These are aromatic compounds containing a prop-2-ylbenzene moiety.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassCumenes
Direct ParentCumenes
Alternative Parents
Substituents
  • Phenylpropane
  • Cumene
  • Phenol ether
  • Monoalkyl phosphate
  • Alkyl phosphate
  • Phosphoric acid ester
  • Organic phosphoric acid derivative
  • Organic phosphate
  • Hydrocarbon derivative
  • Organooxygen compound
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor monitored anaesthesia care sedation in patients undergoing diagnostic procedures like bronchoscopy and colonscopy or minor surgical procedures like arthroscopy and bunionectomy.
PharmacodynamicsFospropofol is a prodrug of propofol, a sedative hypnotic drug. Unlike propofol, fospropofol is water soluble and can be administered in an aqueous solution. 1.86 mg of fospropofol is the molar equivalent for 1mg of propofol.
Mechanism of actionAfter in-vivo conversion of fospropofol into propofol by endothelial alkaline phosphatase, propofol crosses the blood-brain barrier, binds to GABA-A receptors and acts as an agonist. By binding to GABA-A receptor, it will cause an increase in chloride conductance, thus inhibiting the firing of new action potentials in the post-synaptic neuron.
Related Articles
AbsorptionAdequate sedation achieved after 7 minutes with a IV bolus dose of 10mg/kg. It takes 21-45 minutes for patients to recover for fospropopol-induced sedation. Following an intravenous bolus administration of 6 mg/kg in a healthy subject, the pharmacokinetic parameters of fospropofol are as follows: Cmax = 78.7 μg/mL; Tmax = 4 minutes; AUC(0-∞) = 19.0 μg ⋅ h/mL;
Volume of distribution

Fospropofol = 0.33±0.069 L/kg;
Propofol metabolite = 5.8 L/kg.

Protein bindingBoth fospropofol and its active metabolite propofol are highly protein bound (approximately 98%), primarily to albumin. Fospropofol does not affect the binding of propofol to albumin.
Metabolism

Fospropofol is metabolized into propofol, formaldehyde, and phosphate by endothelial alkaline phosphatase. The metabolite, formaldehyde, is quickly oxidized into formic acid by glutathione dependent and independent dehydrogenases and erythrocytes. Excess formic acid is eliminated via oxidation to carbon dioxide through the tetrahydrofolate pathway. Propofol is further metabolized into propofol glucuronide, quinol-4-sulfate, quinol-1-fluronide, and quinol-4-glucuronide. The cytochrome P450 enzyme system is not involved with the metabolism of fospropofol.

SubstrateEnzymesProduct
Fospropofol
Not Available
Formic acidDetails
Fospropofol
Not Available
FormaldehydeDetails
Fospropofol
Not Available
PhosphateDetails
Fospropofol
Not Available
PropofolDetails
Route of eliminationChiefly eliminated by hepatic conjugation to inactive metabolites which are excreted by the kidney. There is negligible renal elimination of unchanged fospropofol (<0.02%).
Half lifeWhen given to a patient, the half-lives are as follows: Fospropofol = 0.81 hours; Propofol metabolite = 1.13 hours
Clearance

Total body clearance (CLp), Fospropofol, healthy subject = 0.28 L/h/kg;
CLp, fospropofol, patients = 0.31 L/h/kg;
CLp/F, propofol, healthy subjects or patients = 2.74 L/h/kg.

ToxicityOverdosage may lead to cardiorespiratory depression, formic acid toxicity (methanol toxicity-like effects), and/or phosphate-induced hypocalemia. Most common adverse reactions (> 20%) are paresthesia and pruritus.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.5105
Blood Brain Barrier+0.8462
Caco-2 permeable-0.546
P-glycoprotein substrateNon-substrate0.6735
P-glycoprotein inhibitor INon-inhibitor0.8244
P-glycoprotein inhibitor IINon-inhibitor0.9747
Renal organic cation transporterNon-inhibitor0.9124
CYP450 2C9 substrateNon-substrate0.8021
CYP450 2D6 substrateNon-substrate0.8086
CYP450 3A4 substrateNon-substrate0.5052
CYP450 1A2 substrateNon-inhibitor0.7667
CYP450 2C9 inhibitorNon-inhibitor0.7807
CYP450 2D6 inhibitorNon-inhibitor0.9205
CYP450 2C19 inhibitorNon-inhibitor0.7375
CYP450 3A4 inhibitorNon-inhibitor0.8538
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8754
Ames testNon AMES toxic0.7212
CarcinogenicityNon-carcinogens0.6902
BiodegradationNot ready biodegradable0.7478
Rat acute toxicity2.3516 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8892
hERG inhibition (predictor II)Non-inhibitor0.926
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Injectionintravenous35 mg/mL
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6204257 No2002-07-012022-07-01Us
US6872838 No1998-08-072018-08-07Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
pKa8.2 - 9.0FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.302 mg/mLALOGPS
logP2.23ALOGPS
logP3.6ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)1.44ChemAxon
pKa (Strongest Basic)-5ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area75.99 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity72.88 m3·mol-1ChemAxon
Polarizability29 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General References
  1. Garnock-Jones KP, Scott LJ: Fospropofol. Drugs. 2010 Mar 5;70(4):469-77. doi: 10.2165/11204450-000000000-00000. [PubMed:20205488 ]
  2. Schywalsky M, Ihmsen H, Tzabazis A, Fechner J, Burak E, Vornov J, Schwilden H: Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats. Eur J Anaesthesiol. 2003 Mar;20(3):182-90. [PubMed:12650488 ]
  3. Bengalorkar GM, Bhuvana K, Sarala N, Kumar T: Fospropofol: clinical pharmacology. J Anaesthesiol Clin Pharmacol. 2011 Jan;27(1):79-83. [PubMed:21804712 ]
  4. Patwardhan A, Edelmayer R, Annabi E, Price T, Malan P, Dussor G: Receptor specificity defines algogenic properties of propofol and fospropofol. Anesth Analg. 2012 Oct;115(4):837-40. Epub 2012 May 14. [PubMed:22584560 ]
External Links
ATC CodesNot Available
AHFS Codes
  • 28:04.92
PDB EntriesNot Available
FDA labelDownload (536 KB)
MSDSDownload (479 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Fospropofol.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Fospropofol.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Fospropofol.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Fospropofol.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Fospropofol.
AlfaxaloneThe risk or severity of adverse effects can be increased when Fospropofol is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Fospropofol.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Fospropofol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fospropofol.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Fospropofol.
AmitriptylineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fospropofol.
AmoxapineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Fospropofol is combined with Amperozide.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fospropofol.
ArticaineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Fospropofol.
AzaperoneThe risk or severity of adverse effects can be increased when Fospropofol is combined with Azaperone.
AzelastineFospropofol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Fospropofol.
BaclofenThe risk or severity of adverse effects can be increased when Fospropofol is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Fospropofol.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Fospropofol.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Fospropofol is combined with Benzyl alcohol.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Fospropofol is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fospropofol.
BrimonidineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Fospropofol.
BrompheniramineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Fospropofol is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fospropofol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Fospropofol.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Fospropofol.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fospropofol.
ButacaineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Fospropofol is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Fospropofol is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Fospropofol.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fospropofol.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Fospropofol.
CarbinoxamineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Fospropofol.
CarisoprodolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Fospropofol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fospropofol.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Fospropofol.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fospropofol.
ChlorphenamineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fospropofol.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fospropofol.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Fospropofol is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fospropofol.
CitalopramThe risk or severity of adverse effects can be increased when Fospropofol is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Fospropofol is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Fospropofol is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Fospropofol.
ClomipramineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Fospropofol is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fospropofol.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Fospropofol.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Fospropofol.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Fospropofol.
CyclizineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fospropofol.
CyproheptadineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Fospropofol is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fospropofol.
DapoxetineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Fospropofol.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Fospropofol.
DesipramineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fospropofol.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Fospropofol.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Fospropofol.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Fospropofol.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Fospropofol.
DifenoxinThe risk or severity of adverse effects can be increased when Fospropofol is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fospropofol.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Fospropofol.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Fospropofol.
DimenhydrinateThe risk or severity of adverse effects can be increased when Fospropofol is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Fospropofol.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Fospropofol.
DoramectinThe risk or severity of adverse effects can be increased when Fospropofol is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Fospropofol is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fospropofol.
DoxylamineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Fospropofol is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Fospropofol.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Fospropofol.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Fospropofol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fospropofol.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Fospropofol.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Fospropofol.
EfavirenzThe risk or severity of adverse effects can be increased when Fospropofol is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Fospropofol.
EntacaponeThe risk or severity of adverse effects can be increased when Fospropofol is combined with Entacapone.
EscitalopramThe risk or severity of adverse effects can be increased when Fospropofol is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Fospropofol.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fospropofol.
EthanolFospropofol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Fospropofol.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fospropofol.
EthosuximideThe risk or severity of adverse effects can be increased when Fospropofol is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Fospropofol is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fospropofol.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Fospropofol.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Fospropofol.
EtidocaineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Fospropofol is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Fospropofol.
EtoperidoneThe risk or severity of adverse effects can be increased when Fospropofol is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Fospropofol.
EzogabineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Fospropofol is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Fospropofol.
FenfluramineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Fospropofol.
FexofenadineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Fospropofol is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Fospropofol.
FlunarizineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Fospropofol.
FluoxetineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Fospropofol.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fospropofol.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fospropofol.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Fospropofol.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fospropofol is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Fospropofol is combined with Fosphenytoin.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fospropofol.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Fospropofol is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Fospropofol.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Fospropofol.
GuanfacineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Fospropofol.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fospropofol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Fospropofol.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Fospropofol.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fospropofol.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Fospropofol.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fospropofol.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fospropofol.
HydroxyzineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Fospropofol is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Indalpine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Fospropofol.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Fospropofol.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Fospropofol.
KetobemidoneThe risk or severity of adverse effects can be increased when Fospropofol is combined with Ketobemidone.
LamotrigineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Fospropofol is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Fospropofol.
LevocabastineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Fospropofol is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Fospropofol.
LevomilnacipranThe risk or severity of adverse effects can be increased when Fospropofol is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Fospropofol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Fospropofol.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Fospropofol.
LofentanilThe risk or severity of adverse effects can be increased when Fospropofol is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fospropofol.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Fospropofol.
Lu AA21004The risk or severity of adverse effects can be increased when Fospropofol is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Fospropofol is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fospropofol.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Fospropofol is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Fospropofol.
MelperoneThe risk or severity of adverse effects can be increased when Fospropofol is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fospropofol.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fospropofol.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Fospropofol.
MetaxaloneThe risk or severity of adverse effects can be increased when Fospropofol is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Fospropofol.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Fospropofol.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Fospropofol.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Fospropofol.
MethocarbamolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Fospropofol.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Fospropofol.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Fospropofol.
MethsuximideThe risk or severity of adverse effects can be increased when Fospropofol is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Fospropofol.
MetyrosineFospropofol may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Fospropofol.
MilnacipranThe risk or severity of adverse effects can be increased when Fospropofol is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fospropofol.
MirtazapineFospropofol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Fospropofol.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Fospropofol.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Fospropofol.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Fospropofol.
NabiloneThe risk or severity of adverse effects can be increased when Fospropofol is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Fospropofol.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Fospropofol.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Fospropofol.
NormethadoneThe risk or severity of adverse effects can be increased when Fospropofol is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Fospropofol.
OpiumThe risk or severity of adverse effects can be increased when Fospropofol is combined with Opium.
OrphenadrineFospropofol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Fospropofol.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Fospropofol.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fospropofol.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Fospropofol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Fospropofol.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fospropofol.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Fospropofol.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Fospropofol.
ParaldehydeFospropofol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Fospropofol.
ParoxetineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Fospropofol.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fospropofol.
PerampanelThe risk or severity of adverse effects can be increased when Fospropofol is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Fospropofol is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Fospropofol.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Fospropofol.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Fospropofol.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Phenoxyethanol.
PhenytoinThe risk or severity of adverse effects can be increased when Fospropofol is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Fospropofol.
PipamperoneThe risk or severity of adverse effects can be increased when Fospropofol is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Fospropofol is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Fospropofol is combined with Pomalidomide.
PramipexoleFospropofol may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Fospropofol.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fospropofol.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Fospropofol.
PrimidoneThe risk or severity of adverse effects can be increased when Fospropofol is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Fospropofol.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fospropofol.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Fospropofol.
PromethazineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fospropofol.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Fospropofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Fospropofol.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Fospropofol.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fospropofol.
RamelteonThe risk or severity of adverse effects can be increased when Fospropofol is combined with Ramelteon.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fospropofol.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fospropofol.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Fospropofol.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Fospropofol.
RomifidineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Romifidine.
RopiniroleFospropofol may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fospropofol.
RotigotineFospropofol may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Fospropofol.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Fospropofol.
ScopolamineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fospropofol.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Fospropofol.
SertralineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fospropofol.
Sodium oxybateThe risk or severity of adverse effects can be increased when Fospropofol is combined with Sodium oxybate.
StiripentolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fospropofol.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Fospropofol.
SuvorexantThe risk or severity of adverse effects can be increased when Fospropofol is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Fospropofol is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Fospropofol.
TetrabenazineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Fospropofol.
ThalidomideFospropofol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Fospropofol.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fospropofol.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Fospropofol.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fospropofol.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Fospropofol.
TiagabineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Fospropofol is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Fospropofol is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Fospropofol.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Fospropofol.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fospropofol.
TrazodoneThe risk or severity of adverse effects can be increased when Fospropofol is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Fospropofol.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fospropofol.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fospropofol.
TrimipramineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Fospropofol.
VigabatrinThe risk or severity of adverse effects can be increased when Fospropofol is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Fospropofol is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fospropofol.
ZiconotideThe risk or severity of adverse effects can be increased when Fospropofol is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Fospropofol.
ZolazepamThe risk or severity of adverse effects can be increased when Fospropofol is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Fospropofol.
ZonisamideThe risk or severity of adverse effects can be increased when Fospropofol is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Fospropofol.
ZotepineThe risk or severity of adverse effects can be increased when Fospropofol is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Fospropofol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB2
Uniprot ID:
P47870
Molecular Weight:
59149.895 Da
References
  1. Franks NP: Molecular targets underlying general anaesthesia. Br J Pharmacol. 2006 Jan;147 Suppl 1:S72-81. [PubMed:16402123 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-gated chloride ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB3
Uniprot ID:
P28472
Molecular Weight:
54115.04 Da
References
  1. Franks NP: Molecular targets underlying general anaesthesia. Br J Pharmacol. 2006 Jan;147 Suppl 1:S72-81. [PubMed:16402123 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
substrate
General Function:
Pyrophosphatase activity
Specific Function:
This isozyme may play a role in skeletal mineralization.
Gene Name:
ALPL
Uniprot ID:
P05186
Molecular Weight:
57304.435 Da
References
  1. Bergese SD, Dalal P, Vandse R, Satlin A, Lin Z, Candiotti K, Cohen L, Gan TJ: A double-blind, randomized, multicenter, dose-ranging study to evaluate the safety and efficacy of fospropofol disodium as an intravenous sedative for colonoscopy in high-risk populations. Am J Ther. 2013 Mar-Apr;20(2):163-71. doi: 10.1097/MJT.0b013e318256ecfc. [PubMed:22820718 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
Comments
comments powered by Disqus
Drug created on May 16, 2010 17:53 / Updated on September 25, 2016 02:15